ErbB2 (HER-2) Monoclonal Antibody (MJD2), eBioscience™, Invitrogen™

Description

Description: This MJD2 monoclonal antibody reacts with HER-2, the product of the ErbB2 gene and a member of the human epidermal growth factor receptor (EGFR) family. HER-2 is a 185 kDa transmembrane receptor with an extracellular binding domain and an intracellular tyrosine kinase domain. Activation of HER-2 occurs following formation of homodimers or heterodimers with ligand-bound EGFR family members, HER3 or HER4. Overexpression of HER-2 results in auto-phosphorylation and increased proliferation and invasiveness and is associated with subsets of multiple cancer types such as breast, ovarian, cervical, uterine, and gastric. The use of HER-2 targeted agents has been used extensively to treat HER-2-positive breast cancer, but a recent study found that these agents can also block the proliferation of breast cancer stem cells found in HER-2-negative patients and suggests the importance of HER-2 as a target for multiple types of breast cancer. The MJD2 antibody recognizes the extracellular domain of HER-2 but at an epitope distinct from that recognized by the 4D5 (Herceptin) and SP3 monoclonal antibodies. Applications Reported: This MJD2 antibody has been reported for use in western blotting, immunohistochemical staining of formalin-fixed paraffin embedded tissue sections, microscopy, and immunocytochemistry.

ErbB2 (HER2) is a receptor tyrosine kinase that is overexpressed in some breast tumors. Herceptin, used in treatment of metastatic Her2-positive cancer, is monoclonal antibody targeting this kinase.